Is this your company? Get featured or correct your listing →
Recent changes
Funding History
1 event · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Aug 27, 2026 | Series C | $120M | — | Pulse story |
Investors
Latest Pulse
- Sep 8, 2026BrainChild Bio Raises $116M for Kids' Brain Cancer TrialBrainChild Bio closed $116 million in Series A financing to fund a pivotal Phase 2 trial of its CAR T-cell therapy for DIPG, a rare and near-uniformly fatal pediatric brain tumor.→
- Aug 27, 2026AusperBio Raises $120M for Hepatitis B CureAusperBio Therapeutics raised a $120 million Series C led by a strategic investor with RA Capital joining, bringing total funding to $360 million as its lead hepatitis B therapy enters Phase 3.→
Coverage Timeline
newest firstAll Coverage
Related Companies
AusperBio Therapeutics FAQ
Who are AusperBio Therapeutics's investors?
AusperBio Therapeutics's investors include RA Capital.
Sources & methodologyshow
Where these figures come from
- BioSpaceresearch database1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.